Patient-reported Outcome (PRO) Measures for Clinical Trials of COPD: The EXACT and E-RS

References

• European Medicines Agency, Respiratory Drafting Group. Guideline on clinical investigation of medicinal products in the treatment of chronic obstructive pulmonary disease (COPD). EMA/CHMP/483572/2012. London: European Medicines Agency; 2012 Jun (cited 2013 February); Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/08/WC500130880.pdf.
   Google Scholar
• Food and Drug Administration. Draft guidance for industry on chronic obstructive pulmonary disease: developing drugs for treatment. Fed Regist 2007; 72(217):63618.
   Google Scholar
• Food and Drug Administration. Guidance for industry on acute bacterial exacerbations of chronic bronchitis in patients with chronic obstructive pulmonary disease: developing antimicrobial drugs for treatment. Fed Regist 2012; 77(190):24035.
   Google Scholar
• European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP), Efficacy Working Party (EWP). Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. EMEA/CHMP/EWP/139391/2004. 2005 Jul (cited 2013 February); Available from: http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003637.pdf.
   Google Scholar
• Food and Drug Administration. Guidance for industry on patient-reported outcome measures: use in medical product development to support labeling claims. Fed Regist 2009; 74(235):65132–65133.
   Google Scholar
• European Medicines Agency, Scientific Advice Working Party of CHMP. Qualification of novel methodologies for drug development: guidance to applicants. EMA/CHMP/SAWP/ 2894/2008 Rev.1. London: European Medicines Agency; 2012 Jan (cited 2013 February); Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004201.pdf.
   Google Scholar
• Food and Drug Administration. Draft guidance for industry on qualification process for drug development tools. Fed Regist Oct 2010; 75(205):65495–65496.
   Google Scholar
• Casaburi R, Celli B, Crapo J, The COPD Biomarker Qualification Consortium (CBQC). COPD. In press.
   Google Scholar
• Coons SJ, Kothari S, Monz BU, Burke LB. The patient-reported outcome (PRO) consortium: filling measurement gaps for PRO end points to support labeling claims. Clin Pharmacol Ther 2011 Nov; 90(5):743–748.
   PubMed Web of Science ®Google Scholar
• Goldman M, Compton C, Mittleman BB. Public-private partnerships as driving forces in the quest for innovative medicines. Clin Transl Med 2013; 2(1):2.
   PubMedGoogle Scholar
• Woosley RL, Myers RT, Goodsaid F. The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science. Clin Pharmacol Ther 2010 May; 87(5):530–533.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Diagnosis, Management, and Prevention of COPD. 2013 Feb (cited 2013 February); Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013Feb13.pdf.
   Google Scholar
• Leidy NK, Wilcox TK, Jones PW, Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measure. Value Health 2010 Dec; 13(8):965–975.
   PubMed Web of Science ®Google Scholar
• Langsetmo L, Platt RW, Ernst P, Bourbeau J. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med 2008 Feb 15; 177(4):396–401.
   PubMed Web of Science ®Google Scholar
• Rennard SI, Leidy NK. Definition and severity of COPD exacerbations. In: Wedzicha W, Martinez F, editors. Exacerbations of chronic obstructive pulmonary disease (COPD). New York, NY: Informa Healthcare; 2009: 1–14.
   Google Scholar
• Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998 May; 157(5 Pt 1):1418–1422.
   PubMed Web of Science ®Google Scholar
• Jones PW, Chen WH, Wilcox TK, Sethi S, Leidy NK. Characterizing and quantifying the symptomatic features of COPD exacerbations. Chest 2011 Jun; 139(6):1388–1394.
   PubMed Web of Science ®Google Scholar
• Leidy NK, Wilcox TK, Jones PW, Standardizing measurement of chronic obstructive pulmonary disease exacerbations. Reliability and validity of a patient-reported diary. Am J Respir Crit Care Med 2011 Feb 1; 183(3):323–329.
   PubMed Web of Science ®Google Scholar
• Sexton C, Leidy NK, Notte SM, Quantifying the severity of respiratory symptoms of COPD: reliability and validity of a patient diary. Poster Presented at the American Thoracic Society International Meeting; 2011 May; Denver, CO.
   Google Scholar
• Houle C, Murray L, Stolar M, Reliability and validity of exacerbations of chronic pulmonary disease tool (EXACT) scores in 3 clinical trials. Poster Presented at the American Thoracic Society International Conference; 2012 May; San Francisco CA.
   Google Scholar
• Murray LT, Houle C, Stolar M, Quantifying the severity of respiratory symptoms of chronic obstructive pulmonary disease (COPD): performance properties of the EXAcerbations of Chronic Pulmonary Disease Tool - Respiratory Symptoms (E-RS) in 3 randomized controlled trials. Poster presented at the American Thoracic Society International Conference; 2012 May; San Francisco, CA.
   Google Scholar
• Halpin DM, Laing-Morton T, Spedding S, A randomised controlled trial of the effect of automated interactive calling combined with a health risk forecast on frequency and severity of exacerbations of COPD assessed clinically and using EXACT PRO. Prim Care Respir J 2011 Sep; 20(3):324–331.
   PubMedGoogle Scholar
• Jones P, Agusti A, Bateman E, Aclidinium bromide in patients with chronic obstructive pulmonary disease: improvement in symptoms and health status in the ATTAIN study. Chest 2011; 140(4_MeetingAbstracts):547A-A.
   Google Scholar
• Jones P, Singh D, Agusti A, Aclidinium bromide in patients with chronic obstructive pulmonary disease (COPD): reduction in exacerbations as defined by health-care utilization and the EXACT diary card. Chest 2011; 140(4_MeetingAbstracts):529A-A.
   Google Scholar
• Singh D, Kampschulte J, Wedzicha JA, A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations. Eur Respir J 2013 Jan; 41(1):12–17.
   PubMed Web of Science ®Google Scholar